NCT01453491 - A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 13, 2012

Primary Completion Date

March 18, 2013

Study Completion Date

March 18, 2013

Conditions

Colitis, Ulcerative

Interventions

DRUG

SRT2104

SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.

Trial Locations (13)

10029

GSK Investigational Site, New York

11021

GSK Investigational Site, Great Neck

20815

GSK Investigational Site, Chevy Chase

21204

GSK Investigational Site, Towson

27612

GSK Investigational Site, Raleigh

38305

GSK Investigational Site, Jackson

42303

GSK Investigational Site, Owensboro

43215

GSK Investigational Site, Columbus

45432

GSK Investigational Site, Beavercreek

48047

GSK Investigational Site, Chesterfield

73104

GSK Investigational Site, Oklahoma City

92801

GSK Investigational Site, Anaheim

06010

GSK Investigational Site, Bristol